-

Blackstone Establishes Structured Finance Group

NEW YORK--(BUSINESS WIRE)--Blackstone (NYSE:BX) today announced the formation of its Structured Finance Group, which brings together Blackstone Real Estate Debt Strategies (“BREDS”) and the firm’s various asset backed finance activities. Jonathan Pollack, currently the Global Head of BREDS, has been named Global Head of the Structured Finance Group. Timothy Johnson, currently the Global Head of Originations for BREDS, will become Global Head of BREDS, overseeing all commercial and residential lending activities.

Rob Camacho will continue to lead the firm’s investment activities in asset based finance. Mike Wiebolt, who currently manages the Real Estate Group’s liquid securities activities, will now also manage asset backed securities.

The formation of this combined group will drive further scale in Blackstone’s lending capabilities across a variety of asset backed finance markets, including consumer finance, real estate, transportation, trade receivables, fund finance, and digital infrastructure.

Jon Gray, President and Chief Operating Officer of Blackstone, said: “This team will capitalize on information across asset classes to deliver unique financing solutions to our clients. The time to expand this part of our business has never been better, particularly as we deploy increasing amounts of insurance capital. Jonathan has done a tremendous job leading BREDS, and we’re excited for him to apply his expertise more broadly.”

Mr. Pollack said: “We believe that direct origination of structured credit investments is integral to delivering differentiated performance for our clients. We are excited to build upon our greatest strengths – broad sourcing capabilities reinforced by deep relationships, large scale capital, and providing tailored solutions to our borrowers and counterparties.”

About Blackstone

Blackstone is the world’s largest alternative asset manager. We seek to create positive economic impact and long-term value for our investors, the companies we invest in, and the communities in which we work. We do this by using extraordinary people and flexible capital to help companies solve problems. Our $731 billion in assets under management include investment vehicles focused on private equity, real estate, public debt and equity, life sciences, growth equity, opportunistic, non-investment grade credit, real assets and secondary funds, all on a global basis. Further information is available at www.blackstone.com. Follow Blackstone on Twitter @Blackstone.

Contacts

Jeffrey Kauth
(212) 583-5395
Jeffrey.Kauth@Blackstone.com

Blackstone

NYSE:BX

Release Versions

Contacts

Jeffrey Kauth
(212) 583-5395
Jeffrey.Kauth@Blackstone.com

More News From Blackstone

Blackstone Announces Joint Venture with Google to Create New TPU Cloud

NEW YORK--(BUSINESS WIRE)--Blackstone (NYSE: BX) today announced a joint venture with Google to create a new U.S.-based company that will offer efficient data center capacity, operations, networking, and Google Cloud's Tensor Processing Units (TPUs) as a compute-as-a-service offering. The company will give customers another option to access cloud TPUs in addition to using them through Google Cloud. Google’s TPUs are custom chips purpose-built for AI, and optimized for training and inference of...

Blackstone Real Estate Debt Strategies Launches Homebuilder Lending Platform

NEW YORK--(BUSINESS WIRE)--Blackstone (NYSE: BX) today announced that Blackstone Real Estate Debt Strategies (“BREDS”) has launched a lending platform that will provide much needed capital and flexibility to homebuilders, and expects to enable the construction of over 50,000 for-sale homes across the United States annually. This lending platform is supported by BREDS portfolio company, Brio Homebuilder Solutions, as well as partnerships with third parties. This commitment comes at a time when t...

Blackstone Life Sciences Invests $250 Million in Anagram Therapeutics to Advance Novel and Patient-Friendly Oral Enzyme Replacement Therapy for Pancreatic Insufficiency

NEW YORK & NATICK, Mass.--(BUSINESS WIRE)--Blackstone Life Sciences (“BXLS”) today announced a $250 million investment in Anagram Therapeutics (“Anagram”), a clinical-stage private biopharmaceutical company dedicated to improving the lives of people living with exocrine pancreatic insufficiency due to cystic fibrosis (“CF”), pancreatic cancer and related disorders. The investment will help fund the further development, approval and launch of Anagram’s ANG003, a novel orally delivered recombinan...
Back to Newsroom